AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00702416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 5 mg im prn q1h (in the postoperative period)
Study NCT00702416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 50 µg iv prn (in the intraoperative period)
Study NCT00702416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 50 µg iv prn (in the intraoperative period)
Study NCT00702416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Will be given in case of block failure and/or patient discomfort intractable with fentanyl during the procedure.~The technique will be left at the discretion of the attending anesthesiologist. Monitored anesthesia care will also be acceptable; the block will be considered as failed in that case as well.
Study NCT00702416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Will be given in case of block failure and/or patient discomfort intractable with fentanyl during the procedure.~The technique will be left at the discretion of the attending anesthesiologist. Monitored anesthesia care will also be acceptable; the block will be considered as failed in that case as well.
Study NCT02286167 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet modification
Description: All patients will be participate in the intermittent, modified Atkins diet
Study NCT03429790 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: intra-operative cell salvage
Description: intra-operative cell salvage collects the patient's blood lost during an operation, processes it and returns it to their own circulation.
Study NCT03429790 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic blood transfusion
Description: transfuse allogeneic blood to patients if blood transfusion is needed.
Study NCT03429790 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: allogeneic blood transfusion
Description: transfuse allogeneic blood to patients if blood transfusion is needed.
Study NCT04023149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human interleukin-2 (rhIL-2)
Description: Drug: rhIL-2; Pharmaceutical form: solution; Route of administration: oral gargle.
Study NCT04023149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Drug: placebo; Pharmaceutical form: solution; Route of administration: oral gargle.
Study NCT05581615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Each intervention provided 10 g/d inulin split into two dosages of 5 g.
Study NCT05581615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: Each intervention provided 10 g/d inulin split into two dosages of 5 g.
Study NCT04124016 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Powder of inulin fractions dissolved into 250 ml of water
Study NCT04124016 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea extract
Description: Powder of green tea extract dissolved into 200 ml of water
Study NCT04124016 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: grape seed
Description: Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol monomers) dissolved into 200 ml of water
Study NCT04124016 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: grape seed extract
Description: Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol oligomers) dissolved into 200 ml of water
Study NCT02876003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-202
Description: G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
Study NCT02760329 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Description: Biomarkers analyses
Study NCT02760329 — intervention group
Intervention type: PROCEDURE
Intervention: Urine
Description: Biomarker analyses
Study NCT02760329 — intervention group
Intervention type: PROCEDURE
Intervention: Lung function measurements
Description: FEV1, FVC, PEF, FEF25-75%, IC, calculated FEV1/FVC ratio and calculated FEV1 % predicted
Study NCT02760329 — intervention group
Intervention type: PROCEDURE
Intervention: Fractional Exhaled Nitric Oxide (FENO)
Description: Measures level of exhaled nitric oxide.
Study NCT02690077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Family-Centered Cesarean
Description: Procedure involves lowering part of the surgical drape exposing a transparent window through which the mother can watch the birth of her baby; the baby will be placed on her chest immediately after the delivery. Cleaning and evaluation of the baby will be done by a nurse who is standing at the head of the bed.
Study NCT02690077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Cesarean
Description: Procedure involves keeping the surgical drape up throughout the entire surgery so that the birthing process will not be visible to the mother, and the baby will be taken to the warmer to be evaluated and cleaned after birth but is available to be laid on the mother's chest at any point upon request.
Study NCT00579657 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control diet, supported by dietary supplement twice daily
Description: control diet, see above
Study NCT00579657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high cereal fiber diet, supported by dietary supplement twice daily
Description: high cereal fiber diet, see above
Study NCT00579657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high protein diet, supported by dietary supplement twice daily
Description: high protein diet, see above
Study NCT00579657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet moderately high both in cereal fiber and protein, supported by dietary supplement twice daily
Description: MIX diet, see above
Study NCT04679597 — intervention group
Intervention type: DRUG
Intervention: Capecitabine
Description: comparison of two treatments
Study NCT04376255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR)
Description: AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
Study NCT03816332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03816332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03816332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT03816332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given PO
Study NCT03483597 — intervention group
Intervention type: OTHER
Intervention: TSQM-II
Description: Treatment Satisfaction Questionnaire for Medication (TSQM Version II) will be used in all groups
Study NCT00930943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER
Description: 40 mg qd twice
Study NCT01759654 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimFlu-V
Study NCT04113681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Geniculate Artery Embolization
Description: 1. Conscious sedation : midazolam and fentanyl~2. Local anesthesia : Lidocaine 2% subcutaneous~3. Retrograde or anterograde common femoral artery access - 4Fr introducer~4. Sub-therapeutic anticoagulation (heparin 2000 IU IA)~5. Lower extremity arteriography~6. Selective and supra-selective catheterization of geniculate arteries supplying painful region of the knee~7. If abnormal arterial blushes are demonstrated selective and supra-selective embolization will be performed with Embozene microspheres (100 microns to 200 microns) - cold saline or ice-packs sac to be applied to overlying skin if significant cutaneous arteries are demonstrated at angiography.~8. Angiographic end-points: embolization of abnormal blush while preserving the parent vessel~9. Arteriotomy closure (manual compression or closure device)
Study NCT02657954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCT
Description: 10-week Compensatory Cognitive Training
Study NCT02657954 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HCE
Description: 10-week Holistic Cognitive Education
Study NCT03347747 — intervention group
Intervention type: OTHER
Intervention: Study Photography + Personal & Medical History Collection
Description: 3D facial images taken and complete a detailed study questionnaire
Study NCT03383003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexium
Description: Esomeprazole ( Nexium )40 mg tid daily for 14 days in the high dose dual therapyarm and 40 mg bid daily for 7 days in the non-bismuth quadruple therapy
Study NCT03383003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium
Description: Esomeprazole ( Nexium )40 mg tid daily for 14 days in the high dose dual therapyarm and 40 mg bid daily for 7 days in the non-bismuth quadruple therapy
Study NCT03383003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amolin
Description: Amoxicillin 750 mg qid daily for 14 days in the high dose dual therapy and amoxicillin 1 g bid daily for 7 days in the non-bismuth quadruple therapy
Study NCT03383003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amolin
Description: Amoxicillin 750 mg qid daily for 14 days in the high dose dual therapy and amoxicillin 1 g bid daily for 7 days in the non-bismuth quadruple therapy
Study NCT03383003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klaricid
Description: clarithromycin 500 mg bid daily for 7 days in the non-bismuth quadruple therapy
Study NCT03383003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flagyl
Description: Metronidazole (Flagyl) 500 mg tid daily for 7 days in the non-bismuth quadruple therapy
Study NCT02901145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab,low dose cyclophosphamide
Description: treatment with IV Nivolumab 3mg/kg every 2 weeks . after a month-addition of low dose cyclophosphamide at a starting dose of 50 mg/kg/day x7 days every 14 days with dose adaptation based on level of Tregulatory cells on follow up immunophenotype.
Study NCT00953199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: 1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP. Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed. If the patient requires more contrast agent, this will be used without the addition of lidocaine.
Study NCT00953199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).
Study NCT00930683 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MEDI-546
Description: 0.1 mg/kg MEDI-546 as a single IV dose
Study NCT00930683 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MEDI-546
Description: 0.3 mg/kg MEDI-546 as a single IV dose
Study NCT00930683 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MEDI-546
Description: 1.0 mg/kg MEDI-546 as a single IV dose
Study NCT00930683 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MEDI-546
Description: 3.0 mg/kg MEDI-546 as a single IV dose
Study NCT00930683 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MEDI-546
Description: 10.0 mg/kg MEDI-546 as a single IV dose
Study NCT00930683 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MEDI-546
Description: 0.3 mg/kg MEDI-546 as a weekly IV dose x 4 doses
Study NCT00930683 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MEDI-546
Description: 1.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
Study NCT00930683 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MEDI-546
Description: 5.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
Study NCT00930683 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MEDI-546
Description: 20.0 mg/kg MEDI-546 as a single IV dose
Study NCT04513678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ImmunOncoTool Condition
Description: Immunotherapy education + irAE monitoring + Facilitation of patient-provider communication
Study NCT01914458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT)
Description: Low-dose computed tomography scan
Study NCT03600090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EOC202
Description: EOC202 will be SC injection.
Study NCT03600090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxol will be IV injection
Study NCT03027063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10,000 steps
Description: Participants will be asked to achieve 10,000 steps daily and to participate in 30 minutes of continuous exercise of their choosing. They will also receive text messages during the week and weekly motivational call
Study NCT03027063 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive the ACC/AHA exercise guidelines
Study NCT03560245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bryostatin
Description: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
Study NCT03560245 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the experimental drug
Study NCT00054925 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personal contact (PC)
Description: This arm uses brief, individual contacts on a monthly basis which emphasize core elements of weight maintenance. Monthly contacts with an interventionist occur for 30 months after the end of Phase I. Face-to-face contacts occur approximately every four months (e.g., three annually), with telephone contacts occurring every month between FTF contacts.
Study NCT00054925 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive technology (IT)
Description: The website utilizes collaborative goal setting and problem-solving strategies to identify contingent action plans for perceived obstacles to success. In order to tailor the intervention to the needs of the participant, the action plan can be updated anytime and as frequently as desired by the individual. Participants are encouraged to input data on weight, food records, physical activity, and goals on a weekly basis. Participants are not restricted to logging on to the website only once a week. Rather, participants have the option of logging on to the website to enter data, communicate with other participants, or to seek other information, as frequently as they wish.
Study NCT03711474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Single dose of Dexamethasone IV or Saline IV given within the first hour of surgery
Study NCT03711474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Single dose of Dexamethasone IV or Saline IV given within the first hour of surgey
Study NCT04489693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory Care Coordinator Team (ACCT)
Description: See arm description
Study NCT04489693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Care Physician Program (CCP)
Description: see arm description
Study NCT04489693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Care Community & Culture Program (C4P)
Description: see arm description
Study NCT04338425 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voice call
Description: Attending surgeons will contact with their patients on the day of surgery after discharge via voice call.
Study NCT00346177 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Stem Cells
Description: Intramyocardial injections
Study NCT00346177 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Stem Cells
Description: Intramyocardial injections
Study NCT01547182 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric restriction
Description: Caloric restriction
Study NCT01547182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Description: Caloric restriction
Study NCT04338425 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video call
Description: Attending surgeons will contact with their patients on the day of surgery after discharge via video call (video conferencing application such as FaceTime or Skype)
Study NCT00337662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 10-20 milligrams (mg), oral, daily, 10 weeks.
Study NCT00337662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: 2-6 mg, oral, daily, for 10 weeks.
Study NCT01547182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: Walking
Study NCT01547182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Lifting weights
Study NCT00337662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: 2-6 mg, oral, daily, 10 weeks
Study NCT03861806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAS true
Description: Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.
Study NCT03519477 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sano Patient Medication Profile
Description: The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to liquid (chromatography/tandem mass-spectrometry) LC/MS/MS-detected drugs from patient blood samples
Study NCT02990299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth for Diabetes Adherence Support
Description: Participants will be paired with a health coach who will provide ongoing support and resources in medication and lifestyle adherence and diabetes self-management. The health coach will perform regular home visits, telephone support and tailored text-messages based on the participant's preferences and needs. They will help assess barriers to adherence and use motivational interviewing to help patients set goals and create action plans. They will also facilitate videoconferences with an assigned clinical pharmacist who will provide consultation on medication use, reconciliation and adherence, identify therapeutic goals and formulate an approved plan of care.
Study NCT03861806 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: PAS sham
Description: Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to not modulate corticospinal excitability.
Study NCT00621816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroprusside
Description: nitroprusside continuous infusion, dose to be titrated to clinical effect
Study NCT00621816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo infusion
Description: blinded placebo infusion, to be infused at same rate as open-label nitroprusside infusion
Study NCT03179813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: During the third molar extraction the hydrocortisone solution will be used in the test group
Study NCT03179813 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: During the third molar extraction the saline solution will be used in the control group
Study NCT02729935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib
Description: 40 mg of intravenous parecoxib 30 min before surgery
Study NCT02729935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An equal volume of saline
Study NCT02101918 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography Perfusion Imaging
Description: Undergo computed tomography perfusion imaging
Study NCT02101918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02101918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ziv-Aflibercept
Description: Given IV
Study NCT03861585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semantic group
Description: The semantic task has to categorise semantically (i.e., type of contexts or type of objects) one image at each trial.
Study NCT00515437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type B (Myobloc)
Study NCT03861585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotional group
Description: The emotional task has to evaluate the emotional content (i.e., neutral, positive or negative) of one image at each trial.
Study NCT00515437 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo to Myobloc